Eupraxia Pharmaceuticals (EPRX) Stock: Buy, Sell, or Hold?
EPRX - Eupraxia Pharmaceuticals Inc. Common Stock
$7.83
-1.27 (-13.96%)
âŧ
5d:
-4.04%
30d:
+23.5%
90d:
+17.04%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When EPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EPRX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EPRX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: EPRX is currently trading at $7.83, which is considered fair relative to its 30-day fair value range of $7.25 to $8.55.
Technical Outlook: Technically, EPRX is in a uptrend. The price is currently testing key support at $7.68. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 14.0% recently.
Market Sentiment: EPRX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $16.35 (+108.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EPRX is in a uptrend. The price is currently testing key support at $7.68. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 14.0% recently.
Market Sentiment: EPRX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $16.35 (+108.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.25 -
$8.55
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-14.0%)
- BULLISH: Trading 108.8% below Wall St target ($16.35)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.25 -
$8.55
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$7.68
Resistance Level
$9.21
Current Trend
Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.52
Wall Street Target
$16.35
(+108.8%)
Share & Embed Analysis
Last updated: October 01, 2026 8:07 PM ET
Data refreshes hourly during market hours. Next update: 9:07 PM
Data refreshes hourly during market hours. Next update: 9:07 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 68 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 63 BUY |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 60 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 68 BUY |
